ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
If you are not happy with the results below please do another search
Tessellate Bio (Naarden, Netherlands; Stevenage, UK) appointed Dr Katie Chapman as Chief Scientific Officer (CSO) at the end of September. She succeeds Dr Jürgen Moll, who will be available to the company in an advisory capacity.
Following Merck Sharp & Dohme (MSD)’s US$10bn acquisition of Verona Pharma and its potential COPD blockbuster Ohtuvayre®, GlaxoSmithKline (GSK) has secured a US$12bn deal for another PDE3/PDE4 inhibitor.
The potential blockbuster HER2 tyrosine kinase inhibitor sevabertinib, developed jointly by Bayer AG and the Broad Institute, is expected to be submitted for regulatory approval in China in Q3 2025 for the treatment of HER2-positive non-small cell lung cancer (NSCLC).
California oral macrocyclic peptide specialist Unnatural Products, Inc. and Dutch-Belgian Argenx SE have formed a multi-target research collaboration aimed at developing oral macrocyclic peptide drugs with UNP’s synthetic macrocycle platform.
In the race to replace MSD’s mega blockbuster pembrolizumab with a more effective bispecific VEGF x PD-(L)1 antibody, German company BioNTech SE has struck a good deal. BioNTech is now developing its Phase III programme BNT327, acquired with the US$950m takeover of Chinese company Biotheus Co Ltd, with Bristol Myers Squibb (BMS) in return for a payment of US$11.1bn.
Join the 3rd BIOTECH SUMMIT AUSTRIA on October 23–24, 2025, in Graz – the heart of Austria’s Medical Science City. This high-level conference connects biotech leaders, innovators, and investors to explore new trends, markets, and opportunities across Europe and beyond.
Dr Regina Hodits joined Angelini Ventures, the VC arm of Angelini Industries, in April as the new Managing Director. She will be based in Germany and lead the company’s international biotech investment strategy with focus Biotech AI and therapeutics.
PHARMAP 2025 brings together experts from all over the world in Berlin, Germany on 14-15 April to share how to make medicine smarter and safer. Leading pharmaceutical companies from the EU, Asia, North America, the Middle East, Africa and others participate in the Congress to find new contacts and expand their network.
WuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
The BIOTECH SUMMIT AUSTRIA 2024 in Innsbruck brought together leaders, innovators and investors to network, interact and to enjoy being part of the booming Austrian biotech community. It showcased science, funding and collaboration opportunities, setting the stage for 2025 in Graz.